Lantheus (NASDAQ:LNTH) issued an update on its FY 2021 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 0.360-0.410 for the period, compared to the Thomson Reuters consensus estimate of $0.370. The company issued revenue guidance of $390 million-$400 million, compared to the consensus revenue estimate of $390.55 million.Lantheus also updated its Q2 guidance to $0.03 to $0.06 EPS.
Shares of LNTH stock traded down $0.79 on Tuesday, hitting $22.89. The stock had a trading volume of 936,570 shares, compared to its average volume of 556,573. The company has a quick ratio of 1.79, a current ratio of 2.25 and a debt-to-equity ratio of 0.40. The business has a 50 day moving average price of $21.27 and a 200 day moving average price of $16.75. The company has a market cap of $1.53 billion, a PE ratio of 286.16 and a beta of 1.32. Lantheus has a one year low of $10.52 and a one year high of $24.26.
Lantheus (NASDAQ:LNTH) last announced its earnings results on Tuesday, May 4th. The medical equipment provider reported $0.05 EPS for the quarter, topping the Zacks’ consensus estimate of ($0.01) by $0.06. The business had revenue of $92.51 million during the quarter, compared to the consensus estimate of $87.24 million. Lantheus had a net margin of 0.12% and a return on equity of 11.05%. The firm’s revenue was up 2.0% on a year-over-year basis. During the same period in the previous year, the company posted $0.36 earnings per share. Equities research analysts expect that Lantheus will post 0.29 EPS for the current year.
A number of brokerages have recently weighed in on LNTH. SVB Leerink boosted their price target on Lantheus from $26.00 to $31.00 and gave the stock an outperform rating in a research note on Tuesday. Credit Suisse Group lifted their target price on shares of Lantheus from $14.00 to $17.00 and gave the company a neutral rating in a research report on Thursday, March 4th. Finally, Zacks Investment Research upgraded shares of Lantheus from a sell rating to a hold rating in a research report on Wednesday, April 28th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company currently has an average rating of Buy and an average target price of $25.67.
In other Lantheus news, CFO Robert J. Jr. Marshall sold 2,280 shares of the business’s stock in a transaction that occurred on Thursday, March 4th. The stock was sold at an average price of $18.40, for a total transaction of $41,952.00. Following the transaction, the chief financial officer now owns 76,985 shares in the company, valued at approximately $1,416,524. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Sam R. Leno sold 5,000 shares of the business’s stock in a transaction that occurred on Thursday, April 8th. The stock was sold at an average price of $21.17, for a total value of $105,850.00. Following the transaction, the director now owns 40,784 shares in the company, valued at approximately $863,397.28. The disclosure for this sale can be found here. Insiders sold a total of 72,188 shares of company stock worth $1,411,148 over the last three months. Insiders own 2.08% of the company’s stock.
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic agents and products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; and RELISTOR for opioid-induced constipation.
See Also: What is a short straddle?
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.